Champions Oncology, Inc. (FRA:2I3)
Germany · Delayed Price · Currency is EUR | Market Cap | 58.67M -26.3% |
| Revenue (ttm) | 52.73M +6.7% |
| Net Income | -986.66K |
| EPS | -0.07 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 170 |
| Open | 4.160 |
| Previous Close | 4.180 |
| Day's Range | 4.080 - 4.180 |
| 52-Week Range | 4.020 - 6.750 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Dec 11, 2026 |
About Champions Oncology
Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice through TumorGraft Technology Platform. It also offers translational oncology solutions that utilizes its technology platform to provide research services that assist in the drug development process of pharmaceutical and biotechnology companies. In addition, the company offers Lumin... [Read more]
News
Champions Oncology Earnings Call Transcript: Q1 2027
Revenue grew 9% year-over-year to $15.2 million, with gross margin rising to 50% and adjusted EBITDA positive for the fifth consecutive quarter. Data licensing revenue exceeded the prior full year in just one quarter, and the company ended with $4.4 million in cash and no debt.
Champions Oncology Earnings release: Q1 2027
Champions Oncology released its Q1 2027 earnings on September 10, 2026, summarizing the period's financial results.
Champions Oncology Quarterly report: Q1 2027
Champions Oncology has published its Q1 2027 quarterly earnings report on September 10, 2026.
Champions Oncology reports Q1 adjusted EPS 5c vs. 1c last year
Reports Q1 revenue $15.2M vs. $14M last year. Robert Brainin, CEO of Champions, commented, “We delivered strong performance in the first quarter of fiscal 2027, with improved study execution and…
Champions Oncology Reports Revenue of $15.2 Million
Oncology services margin improves to 51%; Adjusted EBITDA increases to $671,000 HACKENSACK, NJ / ACCESS Newswire / September 10, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational ...
Champions Oncology to Announce First Quarter Financial Results on Thursday, September 10, 2026
HACKENSACK, NJ / ACCESS Newswire / September 4, 2026 / Champions Oncology, Inc. (CSBR), a global leader in clinically relevant oncology research models and translational solutions, will report its fin...
Champions Oncology expands integrated radiopharmaceutical development platform
Champions Oncology (CSBR) announced the expansion of its integrated radiopharmaceutical development platform with new in-house SPECT/CT imaging capabilities. This capability extends Champions’ existin...
Champions Oncology Proxy statement: Proxy filing
Champions Oncology filed a proxy statement on August 28, 2026, providing details for shareholder voting and corporate governance matters.
Champions Oncology Proxy statement: Proxy filing
Champions Oncology filed a proxy statement on August 28, 2026, providing details for shareholder voting and corporate governance matters.
Champions Oncology reports Q4 adjusted EPS 1c vs. (8c) last year
Reports Q4 revenue $13.8M vs. $12.4M last year. The company noted that a reduction in the cost of oncology revenue reflected continued cost discipline, lower outsourced research services expenses, and...
Champions Oncology Earnings Call Transcript: Q4 2026
Record annual revenue and positive Adjusted EBITDA were achieved, driven by strong core services growth and operational improvements. Data revenue declined due to a non-recurring large transaction, but the customer base expanded and margins improved. Investments position the company for future growth.
Champions Oncology Earnings release: Q4 2026
Champions Oncology released its Q4 2026 earnings on July 27, 2026, summarizing the period's financial results.
Champions Oncology Annual report: Q4 2026
Champions Oncology has published its Q4 2026 annual report on July 27, 2026.
Champions Oncology Reports Record Annual Revenue of $59 Million
Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA HACKENSACK, NJ / ACCESS Newswire / July 27, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a global leader in clinically relevant oncolo...
Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Monday, July 27, 2026
HACKENSACK, NJ / ACCESS Newswire / July 20, 2026 / Champions Oncology, Inc. (NASDAQ:CSBR), a global leader in clinically relevant oncology research models and translational solutions, will report its ...
Champions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026
Eight studies demonstrate how clinically relevant models and integrated data can reduce translational risk and guide development decisions HACKENSACK, NJ / ACCESS Newswire / April 9, 2026 / Champions ...
Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy
Appointment underscores Champions' focus on leveraging clinically relevant data to power next-generation oncology R&D HACKENSACK, NJ / ACCESS Newswire / March 30, 2026 / Champions Oncology, Inc. (Nasd...
Champions Oncology Earnings Call Transcript: Q3 2026
Record core study revenue and positive adjusted EBITDA offset a year-over-year revenue decline due to the absence of data revenue. Early traction in the data business and continued investment in growth initiatives position the company for stronger results in fiscal 2027.
Champions Oncology Quarterly report: Q3 2026
Champions Oncology has published its Q3 2026 quarterly earnings report on March 12, 2026.
Champions Oncology Earnings release: Q3 2026
Champions Oncology released its Q3 2026 earnings on March 12, 2026, summarizing the period's financial results.
Champions Oncology Reports Revenue of $16.6 Million
Company remains on track to deliver year-over-year revenue growth and positive adjusted EBITDA for the fiscal year HACKENSACK, NJ / ACCESS Newswire / March 12, 2026 / Champions Oncology, Inc. (Nasdaq:...
Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 12, 2026
HACKENSACK, NJ / ACCESS Newswire / March 5, 2026 / Champions Oncology, Inc. (CSBR), a leading translational oncology research organization, will report its financial and operational results for the th...
Champions Oncology Earnings Call Transcript: Q2 2026
Revenue grew 11% year-over-year to $15M, with gross margin rising to 52% and adjusted EBITDA at $800K. Strategic investments in radiolabeling and data platforms are driving growth, while the company remains on track for full-year positive adjusted EBITDA.
Champions Oncology Quarterly report: Q2 2026
Champions Oncology has published its Q2 2026 quarterly earnings report on December 15, 2025.
Champions Oncology Earnings release: Q2 2026
Champions Oncology released its Q2 2026 earnings on December 15, 2025, summarizing the period's financial results.